Patents by Inventor Michael E. Osband

Michael E. Osband has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
    Patent number: 5192537
    Abstract: Immunoreactive cells sensitized for an antigenic marker associated with a malignant tumor are prepared in vitro by collecting the tumor patient's own mononuclear cells, depleting suppressor T-cells, suspending the mononuclear cells with serum, preferably autologous, and culturing the cells under conditions to activate and immunize the patient's mononuclear cells against the patient's tumor. Methods of treatment and immunized cells in pharmaceutical presentations are described.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: March 9, 1993
    Assignee: Cellcor Inc.
    Inventor: Michael E. Osband
  • Flow cytometric analysis of histamine receptors
    Patent number: 4474876
    Abstract: A method for analyzing cells to determine whether they have substantial numbers of H1 and H2 histamine receptors. Also an assay kit and a composition for conducting such analyses. The assays involve fluorescent polymeric molecules to which a plurality, preferably from about 30 to about 100, of histamine or histamine blocker molecules are attached. Procedures for optimizing several variables which are essential to effective and reliable determinations.
    Type: Grant
    Filed: November 9, 1981
    Date of Patent: October 2, 1984
    Assignees: Trustees of Boston University, Smithkline Beckman Corporation
    Inventors: Michael E. Osband, Ellen B. Cohen